National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies

Anthony M. Villano, Roberto J. Vidri, Elaine T. Vo, Stephanie H. Greco, Krisha J. Howell, Margaret von Mehren, Jeffrey M. Farma

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: Little level 1 evidence exists to guide multimodality treatment in retroperitoneal soft tissue sarcoma (RPS), which may lead to significant variation in therapeutic approaches. This analysis aimed to describe national RPS treatment trends and explore potential variability among low-/high-volume hospitals (LVH/HVHs). Patients and Methods: In total, 5992 patients who underwent resection for primary RPS were retrospectively identified in the National Cancer Database (2004–2017). Time trend analyses examined rates of multivisceral resection (MVR), radiation, and chemotherapy use. LVHs were defined as those carrying out fewer than ten resections per year (N = 5433), whereas HVHs were defined as those carrying out ten or more (N = 559). Descriptive statistics and logistic regression models compared trends between groups. Results: MVR was more frequent at HVHs (63.7% versus 43.5%, p < 0.001). Use of radiation varied widely by hospital volume. HVHs more frequently employed preoperative radiation as compared with LVHs (14.7% versus 8.1%, p < 0.001). Throughout the study period, LVHs increased utilization of preoperative radiation (2.6% to 12.0%, p < 0.001) whereas rates at HVHs remained stable. Overall, LVHs utilized postoperative radiation significantly more frequently as compared with HVHs (14.7% versus 2.7%, respectively, p < 0.001). Postoperative radiation at LVHs remained stable until 2013 and sharply declined thereafter (16.7% to 6.9%, p < 0.001). Rates of postoperative radiation use at HVHs remained lower than those at LVHs at all time points. Conclusions: Strategies for resection and radiation use at LVHs have trended towards those of HVHs. Current national implementation of preoperative radiation, MVR, and chemotherapy remains heterogeneous. These findings inform future trial design and support standardization of care.

Original languageEnglish
Pages (from-to)2275-2285
Number of pages11
JournalAnnals of Surgical Oncology
Issue number4
StatePublished - Apr 2022


  • Hospitals, High-Volume
  • Hospitals, Low-Volume
  • Humans
  • Retroperitoneal Neoplasms/radiotherapy
  • Retrospective Studies
  • Sarcoma/radiotherapy


Dive into the research topics of 'National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies'. Together they form a unique fingerprint.

Cite this